Age (median) (min-max) |
55,5±15,4 (18,0-91,0) |
65,5 (36,0-91,0) |
54,0
(18,0-88,0) |
<0,001 |
Age group(n,%)
<50 age
50-64 age
≥ 65 age
|
151 (35,8%)
151 (35,8%)
120 (28,4%)
|
2 (%3,9)
23 (%45,1)
26 (%51,0)
|
149 (%40,2)
128 (%34,5)
94 (%25,3)
|
<0,001
|
Gender (n,%)
Male
Female
|
252 (59,7%)
170 (40,3%)
|
37 (%72,5)
14 (%27,5)
|
215 (%58,0)
156 (%42,0)
|
0,046
|
BMI (median) (min-max) |
26,3±4,2 (16,8-46,9) |
24,5 (18,9-39,2) |
25,4
(16,8-46,9) |
0,142 |
BMI group (n,%)
Thin
Normal
Preobese
Obese
|
5 (%1,2)
189 (%44,8)
156 (%37,0)
72 (%17,1)
|
0 (%0,0)
26 (%51,0)
20 (%39,2)
5 (%9,8)
|
5 (%1,3)
163 (%43,9)
136 (%36,7)
67 (%18,1)
|
0,383
|
Obesity (n,%) |
72 (17,0 %) |
5 (%9,8) |
67 (%18,1) |
0,142 |
Overweight (n,%) |
51 (12,0%) |
25 (%49,0) |
26 (%51,0) |
0,444 |
Cigarette (n,%)
Smoker
Exsmoker
Nonsmoker
|
64 (%15,2)
119 (%28,2)
239 (%56,6)
|
5 (%9,8)
32 (%62,7)
14 (%27,5)
|
59 (%15,9)
87 (%23,5)
225 (%60,6)
|
<0.001
|
Cigarette (n,%)
Ever smoker
Non smoker
|
183 (43,3%)
239 (56,6%)
|
37 (%72,5)
14 (%27,5)
|
146 (%39,4)
225 (%60,6)
|
<0,001
|
Blood Group (n,%)
A
B
AB
0
|
174 (%41,2)
74 (%17,5)
52 (%12,3)
122 (%28,9)
|
16 (%31,4)
9 (%17,6)
11 (%21,6)
15 (%29,4)
|
158 (%42,6)
65 (%17,5)
41 (%11,1)
107 (%28,8)
|
0,145
|
Pneumonia (n,%)
Mild
Middle
Severe
|
182 (%43,1)
153 (%36,3)
87 (%20,6)
|
8 (%15,7)
2 (%3,9)
41 (%80,4)
|
174 (%46,9)
151 (%40,7)
46 (%12,4)
|
<0.001
|
PCR (n,%)
Positive
Negative
|
306 (72,5%)
116 (27,4%)
|
45 (%88,2)
6 (%11,8)
|
261 (%70,4)
110 (%29,6)
|
0,007
|
Comorbidity (n,%)
yes
No
|
234 (%55,5)
188 (%44,5)
|
42 (%82,4)
9 (%17,6)
|
192 (%51,8)
179 (%48,2)
|
<0.001
|
Comorbidity (n,%)
No
Single
Multiple
|
188 (%44,5)
118 (%28,0)
116 (%27,5)
|
9 (%17,6)
19 (%37,3)
23 (%45,1)
|
179 (%48,2)
99 (%26,7)
93(%25,1)
|
<0.001
|
COPD(n,%) |
64 (%15,2) |
14 (%27,5) |
50 (%13,5) |
0,009 |
Cardiac Diseases (n,%) |
70 (%16,6) |
14 (%27,5) |
56 (%15,1) |
0,026 |
Hypertansion (n,%) |
109 (%25,8) |
19 (%37,3) |
90 (%24,3) |
0,047 |
Diabetius mellitus(n,%) |
64 (%15,2) |
11 (%21,6) |
53 (%14,3) |
0,174 |
Asthma(n,%) |
19 (%4,5) |
3 (%5,9) |
16 (%4,3) |
0,612 |
Serebrovasculer disease (n,%) |
18 (%4,3) |
4 (%7,8) |
14 (%3,8) |
0,178 |
Malignancy (n,%) |
53 (%12,6) |
19 (%37,3) |
34 (%9,2) |
<0,001 |
Using ACE Inhbitor (n,%)
Present
Absent
|
105 (%24,9)
317 (%75,1)
|
21 (%41,2)
30 (%58,8)
|
84 (%22,6)
287 (%77,4)
|
0,004
|
Radyological progression (n,%)
Present
Absent
|
68 (16,1%)
349 (82,7%)
|
35 (%68,6)
16 (%31,4)
|
33 (%9,0)
333 (%91,0)
|
<0,001
|